Pam Cheng - AstraZeneca PLC President
| AZNCF Stock | USD 125.50 0.80 0.64% |
President
Ms. Pam P. Cheng is Executive Vice President Operations and Information Technology of the Company. She joined AstraZeneca in June 2015 after having spent 18 years with MerckMSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management Logistics for Merck from 2006 to 2011 and led the transformation of Merck supply chains across the global supply network. More recently, Pam was President of MSD China, responsible for MSDs entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelors and Masters degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York. In addition to her role at AstraZeneca, Pam serves as a nonexecutive Director of the Codexis Inc. Board . Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering Board of Directors. since 2015.
| Age | 52 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sergey Brin | Alphabet Inc Class C | 50 | |
| Albert Bourla | Pfizer Inc | 59 | |
| Mikael Dolsten | Pfizer Inc | 62 | |
| John Carruthers | Enbridge | N/A | |
| John Whelen | Enbridge | 58 | |
| Sally Susman | Pfizer Inc | 59 | |
| Cynthia Hansen | Enbridge | 59 | |
| Rady Johnson | Pfizer Inc | 62 | |
| Douglas Lankler | Pfizer Inc | 58 | |
| Dawn Rogers | Pfizer Inc | 54 | |
| Emma Walmsley | GSK plc | 53 | |
| David Bell | Grifols SA ADR | 70 | |
| Frank DAmelio | Pfizer Inc | 66 | |
| Robert Rooney | Enbridge | 63 | |
| Byron Neiles | Enbridge | 53 | |
| Alberto Roura | Grifols SA ADR | 65 | |
| Angela Hwang | Pfizer Inc | 58 | |
| Ruth Porat | Alphabet Inc Class C | 66 | |
| Vernon Yu | Enbridge | 54 | |
| Colin Gruending | Enbridge | 54 | |
| Alexander Mackenzie | Pfizer Inc | 60 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Gonzalo Vina, Head Relations | ||
| Aradhana MD, CFO Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.